Back

Predicted lifetime therapy benefit guided treatment effectively reduces residual cardiovascular risk in patients with symptomatic atherosclerotic disease

29 August 2020 (10:02 - 10:11)
Organised by:
Congress Presentation Part of: Young Investigator Award Session Population Sciences Cardiovascular Risk Assessment ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Steven Hageman

University Medical Center Utrecht, Utrecht (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Regular exercise after a diagnosis of atrial fibrillation and lower risks of cardiovascular disease: a nationwide population-based study
Doctor H. Ahn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Effect of beta blocker therapy following myocardial infarction in optimally treated patients in the reperfusion era - a Danish, nationwide, and registry-based cohort study
Doctor A. Holt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
The association of artificial intelligence-enabled electrocardiogram-derived age (physiologic age) with atherosclerotic cardiovascular events in the community
Doctor J. Medina-Inojosa (Atlanta, US)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session Population Sciences
Video

The Event

Event poster

ESC Congress 2020

29 August 2020 10:02 CET
You may be interested in
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Update on dyslipidaemia management: focus on risk estimation and lipoprotein(a)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources